During a two-year follow-up, 5,037 patients taking a GLP-1 developed diabetic retinopathy, compared with 4,938 who were not a 7% increased risk
Some individuals prefer morning administration as it fits naturally into their daily routine alongside other morning activities
The semaglutide drugs most commonly discussed in connection with NAION litigation are: Ozempic Wegovy Rybelsus Other GLP-1 drugs have also been named in broader vision-loss litigation, but the semaglutide products have received the most attention from regulators, researchers, and current lawsuits
Adolescents may experience significant pressure from parents, peers, and society to lose weight, potentially compromising their ability to make truly autonomous decisions about treatment
Continuous treatment is needed to maintain improvement in weight and health. Eli Lilly, frontrunner in commercializing GLP-1 analogs, eyes obesity treatment market Eli Lilly has long dominated the GLP-1 analog market with its diabetes treatment Trulicity (dulaglutide)
